#BCISACI day 2 highlights ❤️‍🔥 TAVI talks, mitral TEER live, a cracking keynote speech, and the young investigator award! Prof Banning Sam Dawkins Dr Phil Hammond 💙 Aish Sinha Professor Vijay Kunadian #ACI2024 #cardiotwitter

How a crazy idea led to a clinical revolution. "To all those who believe that we as cardiologists can make a difference in our commitment to ideas, TAVI stands as an example of what such an idea can produce." Rest in peace, Professor Cribier. eurointervention.pcronline.com/article/tavi-a…

#Colchicine and residual #inflammation: an old drug with a new trick 💊 An editorial for British Cardiovascular Society 👇 britishcardiovascularsociety.org/resources/edit… #colcot #lodoco2 #ASCVD

Original Article: Microplastics and Nanoplastics in Atheromas and Cardiovascular Events nej.md/3IrM6T8 Editorial: Plastics, Fossil Carbon, and the Heart nej.md/48CvGSs #PublicHealth

How come data be so misrepresented by Royal College of Physicians before a vote and halfway through the vote when the actual data is released is so damning that it could potentially change the way people vote. Doctors up and down the country have been voting based on misleading data and the

Composite outcomes and making sense of the #winratio 🧐 An editorial for British Cardiovascular Society >> britishcardiovascularsociety.org/resources/edit… #medicalstatistics #clinicaltrials #CardioTwitter

Astonishing results from the DanGer Shock Trial presented at #ACC24 and out in NEJM today. In patients with ST-elevation MI with cardiogenic shock, Impella reduced all-cause mortality (45.8% Impella vs. 58.5% control) at 180 days. Some thoughts on this ground breaking trial:

Be skeptical of the findings in single-centre RCTs of critically ill patients published in high-impact journals claiming a mortality benefit. Only 1 out of 16 RCTs were replicated in a multi-centred RCT. ccforum.biomedcentral.com/articles/10.11… Justin Morgenstern #hello I'm Dr Kirsty 🏳️‍🌈 John Mandrola, MD Adam Cifu

An important observation👇🏻 The majority of *major* cardiology trials are under powered to sort signal from noise. Just as Frank Harrell points out nearly every week. This is bad for our field.

After a sunny few days in Paris, the clouds have opened up, just in time to get stuck in at #europcr ! 🤩

Fantastic morning supporting friends and colleagues #europcr Florentina Simader affirming that ‘typical’ symptoms really are the strongest predictor of symptom benefit from PCI #orbita2 Matt Hammond-Haley asks ‘do our patients actually have microvascular angina?’

We are THRILLED to have been ranked 2nd in the world and 1st in the UK and Europe in this year's QS QS World University Rankings! 🎊🥳 #QSWUR Thank you to everyone in #OurImperial community for making this result possible! 💙

The academic fantasy

A reminder of the potential of colchicine in addressing inflammation as a CV risk - slide from Dr Kayla Chiew at #bcs2024

This is a study inspired from and dedicated to Sanjay Kaul, where we investigated the effect of using absolute rather than relative noninferiority margins in cardiovascular randomized trials. Recalculating noninferiority margins based on actual event rates, rather than expected

It’s late in London but here’s my hot take of the ABYSS trial #ESCCongress — Okay to stop beta blockers after MI (good EF) medscape.com/viewarticle/be…

The SENIOR-RITA trial found that an invasive strategy involving coronary revascularization plus medical therapy did not significantly reduce the risk of cardiovascular death or nonfatal myocardial infarction compared to a conservative medical therapy approach in older patients

Systematic review of 43 studies on microvascular angina revealed heterogeneity in diagnostic criteria and limited evidence for effective treatment strategies. Highlighted the necessity of high-quality, randomized trials to guide clinical management. Read more: